Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neulasta and Aranesp in dose-dense breast cancer chemotherapy
NCT00261313Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2005
- Primary completion
- Jun 2007
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim and darbepoetin alfa in breast cancer, sponsored by Amgen. Primary endpoint: Proportion of subjects experiencing any delay in any cycle of chemotherapy at 3 months. Started Dec 2005; status: completed.
02
Drugs
pegfilgrastimdarbepoetin alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00261313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261313.